Cartalax 20mg
$49.99
- Compound: Cartalax 20mg
- Sequence: H-Ala-Glu-Asp-OH
- Molecular Formula: C12H19N3O8
- Molecular Weight: 333.11721457 g/mol
- PubChem CID: 87815447
- CAS Number: N/A
- Vial Size: 3mL
- Intended Use: Controlled laboratory research only
50 in stock
Cartalax 20mg – Advanced Peptide Research Material
Cartalax 20mg is a research material supplied in a 3mL vial with the sequence H-Ala-Glu-Asp-OH. The supplied molecular formula is C12H19N3O8, with a molecular weight of 333.11721457 g/mol and PubChem CID 87815447.
These molecular specifications provide reference information for material identification, laboratory documentation, and comparison with appropriately matched scientific records.
Cartalax 20mg Research Overview
The supplied research material has the following specifications:
| Specification | Product Information |
|---|---|
| Compound | Cartalax |
| Quantity | 20mg |
| Sequence | H-Ala-Glu-Asp-OH |
| Molecular Formula | C12H19N3O8 |
| Molecular Weight | 333.11721457 g/mol |
| PubChem CID | 87815447 |
| CAS Number | N/A |
| Vial Size | 3mL |
The 20mg quantity describes the amount of material supplied. The 3mL specification describes vial capacity and does not independently establish an experimental concentration or preparation volume.
Molecular Specifications
The supplied sequence is:
H-Ala-Glu-Asp-OH
The molecular formula is:
C12H19N3O8
The stated molecular weight is:
333.11721457 g/mol
The supplied PubChem identifier is 87815447.
Researchers can also examine records associated with the supplied formula through the PubChem molecular formula search for C12H19N3O8.
The supplied CAS field is listed as N/A, so no CAS number is being inferred or added.
Peptide Research Identification
Material identification should use the complete supplied molecular characteristics rather than relying solely on a commercial or abbreviated product name.
For this product, relevant identifying information includes:
- H-Ala-Glu-Asp-OH sequence
- C12H19N3O8 molecular formula
- 333.11721457 g/mol molecular weight
- PubChem CID 87815447
- 20mg material quantity
- 3mL vial capacity
These specifications can be recorded alongside experiment-specific information to improve research documentation and comparison.
Cartalax Peptide Protocol – Research Context
The phrase cartalax peptide protocol reflects search interest concerning experimental procedures.
A research protocol should be determined according to the specific laboratory model, objective, analytical methodology, and validated experimental design rather than being inferred from the quantity supplied in a vial.
Important protocol variables may include:
- Material identity
- Experimental model
- Research concentration
- Appropriate controls
- Sample preparation
- Exposure conditions
- Analytical methodology
- Observation period
- Experimental endpoints
- Reproducibility requirements
The 20mg specification on this product describes supplied material quantity. It is not a recommended dose or universal experimental concentration.
No solvent, preparation procedure, or experimental concentration was supplied with the product information, so none is being invented.
Cartalax Peptide Side Effects – Research Safety Context
Searches for cartalax peptide side effects should be distinguished from controlled laboratory safety assessment.
The supplied product specifications do not provide clinical safety, adverse-event, toxicity, or human-use data. Therefore, this page does not make claims about established human side effects.
Within laboratory research, safety-related observations should be evaluated according to appropriately matched experimental evidence and the specific model being investigated.
Researchers should distinguish between:
- Controlled experimental observations
- Preclinical findings
- Published scientific evidence
- Anecdotal reports
- Unsupported personal-use claims
Evidence from one research model should not automatically be generalized to humans or to a substantially different experimental system.
Buy Cartalax USA – Research Procurement Context
The phrase buy cartalax usa represents commercial search intent around obtaining this research material.
For laboratory procurement, researchers should prioritize documented product characteristics rather than relying only on commercial search terminology.
Relevant specifications for evaluation can include:
- Compound name
- Material quantity
- Sequence
- Molecular formula
- Molecular weight
- Database identifiers
- Vial format
- Research documentation
This listing is presented for research procurement only and does not recommend personal consumption, self-administration, or therapeutic use.
20mg Material in a 3mL Vial
The product contains 20mg of specified research material and is supplied in a 3mL vial.
These are separate physical product specifications.
The vial capacity does not establish a final concentration, and the material quantity does not constitute a recommended experimental or human dose.
No preparation solvent, reconstitution instructions, storage conditions, or shelf-life information was supplied in the provided specifications.
Those details are therefore not being inferred.
Laboratory Research Considerations
Controlled peptide investigation requires clearly documented experimental methodology.
Relevant variables can include:
- Molecular identity
- Sequence
- Material quantity
- Research concentration
- Experimental model
- Appropriate controls
- Sample preparation
- Exposure conditions
- Analytical techniques
- Experimental endpoints
- Data interpretation
Differences in these variables can affect whether results from separate experiments can reasonably be compared.
Experimental Documentation
Researchers working with this material can maintain records of both molecular and experiment-specific information.
Product documentation may include:
Compound: Cartalax
Quantity: 20mg
Sequence: H-Ala-Glu-Asp-OH
Formula: C12H19N3O8
Molecular Weight: 333.11721457 g/mol
PubChem CID: 87815447
CAS Number: N/A
Vial Capacity: 3mL
Experiment-specific records may additionally include concentration, research model, controls, methodology, exposure conditions, and measured endpoints.
Evaluating Scientific Literature
Scientific literature should be evaluated according to the exact material and experimental methodology used.
Researchers should verify factors such as:
- Molecular identity
- Sequence
- Research model
- Experimental concentration
- Study design
- Appropriate controls
- Analytical methodology
- Experimental endpoints
A similarly named research material should not automatically be considered molecularly or experimentally equivalent.
Likewise, findings produced under substantially different experimental conditions may not be directly comparable.
Related OROS Research Materials
Researchers can explore OR-3R 10mg / Elora 5mg as a separately specified research blend.
Another catalog option is Elora 5mg.
Researchers can also review OR-1S 5mg and OR-1S 10mg as independently specified research products.
Each material has separate product characteristics and should be evaluated according to its own specifications.
Scientific Research Resources
Researchers can use PubChem to investigate available molecular records, identifiers, and compound information.
Peer-reviewed biomedical and experimental literature can be searched through PubMed.
Researchers should verify that a publication involves the relevant molecular material, research model, concentration, controls, methodology, and endpoints before comparing its findings with another experiment.
Research FAQ
What is Cartalax 20mg?
Cartalax 20mg is supplied as a peptide research material with the sequence H-Ala-Glu-Asp-OH in a 3mL vial.
What is the supplied sequence?
The sequence is H-Ala-Glu-Asp-OH.
What is the molecular formula?
The supplied molecular formula is C12H19N3O8.
What is the molecular weight?
The supplied molecular weight is 333.11721457 g/mol.
What is the PubChem CID?
The supplied PubChem CID is 87815447.
What is the CAS number?
The supplied product information lists the CAS field as N/A. No alternative CAS number is being inferred.
Is there a Cartalax peptide protocol?
No universal protocol is provided here. Laboratory parameters should be established according to the research model, experimental objectives, validated methodology, and appropriate controls.
What are the Cartalax peptide side effects?
The supplied specifications do not provide clinical safety or human adverse-event data. This research listing therefore does not establish human side effects or provide individualized medical guidance.
Research Use Disclaimer
This Cartalax 20mg material is presented exclusively for controlled laboratory investigation, analytical evaluation, and applicable in-vitro research. Material quantity and vial capacity are research specifications and do not constitute human dosing or administration guidance. This information does not provide instructions for injection, self-administration, therapeutic use, diagnosis, treatment, or veterinary application.
| Net Weight |
20mg |
|---|---|
| Brand |
OROS Research |
| Format |
Lyophilized Vial |

Reviews
There are no reviews yet.